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ABSTRACT
Remission is the optimum treatment target for patients with rheumatoid arthritis. With the advent 
of biologic therapies, and the use of treat to target strategies, many more patients are achieving 
remission. Once a patient has achieved a period of sustained remission, there is little to guide 
subsequent management and patients usually continue treatment long-term. This may be inap-
propriate. Recent evidence suggests that some patients may be able to reduce or even stop therapy 
KRZHYHUWKHLGHDOSDWLHQWSUR¿OHLV\HWWREHGHWHUPLQHG3RWHQWLDOSUHGLFWRUVKDYHEHHQLGHQWL-
¿HGKRZHYHUKDYHQRWHQWHUHGURXWLQHFOLQLFDOSUDFWLFH7KHUHLVDQHHGIRUUREXVWELRPDUNHUVWR
facilitate the prediction of successful tapering.
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primary pathology is synovitis, which results in joint destruction.2 This occurs as a result of 
immune system dysfunction, in which loss of self-tolerance triggers antibody production and 
F\WRNLQHPHGLDWHGV\QRYLDOSUROLIHUDWLRQ3
Sub-optimal treatment of RA results in substantial joint pain, disability, adverse social conse-
quences and increased mortality compared to the general population.2 Furthermore, RA is a dis-
ease of considerable socioeconomic burden.4,5 Since there is no cure, the optimum treatment 
target is remission,6FODVVLFDOO\GH¿QHGDVDGLVHDVHDFWLYLW\VFRUH'$6RIIDLOLQJWKLV
DVWDWHRIORZGLVHDVHDFWLYLW\/'$'$677KLVLQYROYHVWKHUDSLGFRQWURORILQÀDP-
mation to prevent structural damage and maintain function. In clinical practice this is usually 
achieved through treat to target (T2T) strategies, which employ strict monitoring of disease ac-
WLYLW\XVLQJFRPSRVLWHPHDVXUHVHJ'$6DQGIRFXVRQVXFFHVVLYHHVFDODWLRQRILPPXQRVXS-
pressive agents (conventional synthetic and biologic disease modifying drugs (csDMARDs and 
bDMARDs respectively), used alone or in combination).
$OWKRXJK77 VWUDWHJLHV KDYH OHG WR VLJQL¿FDQW LPSURYHPHQWV LQ SDWLHQW RXWFRPHV10-12 there 
is little to guide clinical practice on how to manage remission once it has been achieved. Ap-
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SUR[LPDWHO\  RI SDWLHQWV DFKLHYH VXVWDLQHG UHPLVVLRQ
(6 months or longer) following treatment.13 Typically these pa-
tients continue their immune-modulatory treatment long-term, 
which may be inappropriate. For those who achieve sustained 
'$6UHPLVVLRQFOLQLFDOH[SHULHQFHFRPELQHGZLWKGDWDIURP
de-escalation and registry studies suggest that treatment may be 
optimised through either dose tapering (de-intensifying treat-
ment) or discontinuation, whilst maintaining the same treatment 
goals.13-15 However, it is unclear whether successful drug cessa-
WLRQ LVDFRQVHTXHQFHRI WKHQDWXUDOGLVHDVHFRXUVHRU LV LQÀX-
HQFHGE\WUHDWPHQWUHJLPH3DWKRJHQHWLFDQGHQYLURQPHQWDOIDF-
tors e.g. shared epitope status, anti-citrullinated protein antibody 
$&3$SRVLWLYLW\ DQG VPRNLQJ VWDWXVPD\DOVREH VLJQL¿FDQW
contributors to the outcome.16
Both the European League Against Rheumatism (EULAR) and 
the American College of Rheumatology (ACR) recommend ta-
pering of treatment after the achievement of remission not LDA 
GXH WR WKH SUHVHQFH RI UHVLGXDO LQÀDPPDWLRQ 7KH\ DGYLVH D
VSHFL¿FVHTXHQFHRIUHGXFWLRQEDVHGRQFRVWDQGH൵HFWLYHQHVV
(starting with corticosteroids, bDMARDs then csDMARDs). 
They also highlight that the basis of this decision should be a 
combination of patient preference and physician judgement. 
+RZHYHU WKHUH LV D ODFN RI FRQVHQVXV RQ KRZ WR GHOLYHU WKLV
approach.7REHDEOH WRR൵HU WDSHULQJRUGLVFRQWLQXDWLRQRI
bDMARDs, clinicians need to be able to identify the ideal pa-
WLHQWSUR¿OHXVLQJUREXVWELRPDUNHUVZKLFKFDQSUHGLFWVXFFHVV-
ful tapering.
In addition to describing the rationale for tapering and provid-
ing a summary of existing studies, this review aims to present 
HYLGHQFHIRUWKHXVHRIPRUHREMHFWLYHELRPDUNHUVWRSUHGLFWVXF-
cessful tapering and potentially discontinuation of bDMARDs 
(with a focus on tumour necrosis factor inhibitors, TNFi) for RA 
patients in stable remission.
WHY TAPER?
The concept of dose tapering (towards discontinuation), for bD-
MARDs is appealing for several reasons. First, maintaining full 
doses of treatment in patients who are well could be regarded 
as over-treatment, potentially subjecting them to an unnecessary 
ULVNRIWR[LFLW\$OWKRXJKWKHDGYHUVHH൵HFWVRIE'0$5'VUH-
SRUWHGLQFOLQLFDOWULDOVLVJHQHUDOO\ORZWKH\FDQSRVHDVLJQL¿-
FDQW VDIHW\ ULVNRIDGYHUVH UHDFWLRQVSDUWLFXODUO\ LQIHFWLRQDQG
malignancy (dose-dependent) plus neurological and cardiovas-
cular morbidity. This is particularly relevant for inhibitors 
TNFis. bDMARDs are also associated with high costs, being 
more expensive than csDMARDs.21,22 From a patients perspec-
tive, patients who are well frequently express the desire to re-
duce their treatment or have a drug-holiday due to the burden 
RIWDNLQJWDEOHWVVHOILQMHFWLQJDQGFRQFHUQVUHJDUGLQJORQJWHUP
VLGHH൵HFWV23,24 This frequently leads to poor adherence to thera-
S\ZLWKSDWLHQWVVHOIGLVFRQWLQXLQJWUHDWPHQWLQRIFDVHV25 
7KLVSRVHV WKHULVNRI LQFUHDVHGPRUELGLW\ WKURXJKVXEVHTXHQW
loss of disease control when not based on predictive criteria.
There is also a separate pharmacodynamic rationale supporting 
targeted dose-tapering of bDMARDs in a proportion of patients. 
bDMARDs classically manifest their action after achieving a 
minimal serum drug concentration, which is maintained over a 
VSHFL¿FWLPHLQWHUYDOEHWZHHQWZRFRQVHFXWLYHDGPLQLVWUDWLRQV
The half-life and volume of distribution of the drug may vary 
between patients, therefore the dose required to achieve the 
minimum serum drug concentration can also vary.26 Therefore, 
SDWLHQWV VKRXOGEH DEOH WR WDSHU GRZQXQWLO DPLQLPXPH൵HF-
tive concentration is reached. The minimum serum drug con-
centration can also vary between patients; thus each patient is 
thought to have their own dose-response curve. Several varia-
tions may be possible, as described by Fautrel et al. Conceptu-
ally, some patients have an average response curve, meaning that 
WKH\FRXOGFRQVLGHUWDSHULQJDVWKHFOLQLFDOH൵HFWLVQRWUHODWHG
to treatment. Others may have a good response to a lower dose 
(left-shift), therefore may be subject to over-treatment using cur-
rent treatment strategies or a good response to a higher dose only 
(right-shift). To complicate matters, some patients may achieve 
only a partial response, or no response at all, therefore poten-
WLDOO\VXEMHFWLQJSDWLHQWV WRDQLQFUHDVHGULVNRIPRUELGLW\GXH
WRODFNRIUHVSRQVH,QWKLVFDVHLWPD\EHSODXVLEOHWRFRQVLGHU
switching to an alternative drug. A potential issue to consider 
ZKHQWDSHULQJLVWKHµQRFHER¶H൵HFWLQZKLFKDUHGXFHGGRVHLV
perceived as inferior, thus resulting in a perceived deterioration 
RIGLVHDVHFRQWURO7KHUHLVDOVRDULVNRIDWWULEXWLRQZKHQDGLV-
HDVHÀDUHIROORZLQJGRVHWDSHULQJLVDWWULEXWHGWRWKHORZHUGRVH
when, in fact it may be a result of the natural disease course.21
Conversely, there is the danger that tapering of therapy leads to 
PRUH IUHTXHQW GLVHDVH ÀDUHV ZLWK LPSDFW RQ D SDWLHQW¶V TXDO-
ity of life and function. There is also the concern that disease 
control may not be re-captured with the re-commencement of 
prior therapy, thus accelerating disease progression.21 Reassur-
ingly, however, evidence suggests that control is re-captured in 
DSSUR[LPDWHO\RISDWLHQWVZLWKLQPRQWKV and is 
not associated with more adverse events or higher immunoge-
nicity.
Overall, it is felt that tapering, especially when evidence based, 
VKRXOGUHSUHVHQWDEHWWHUULVNEHQH¿WSUR¿OHPDLQWDLQLQJFOLQL-




'RVHWDSHULQJGLVFRQWLQXDWLRQ RI E'0$5'V has been tested 
in RA patients in both observational studies and randomised 
controlled trials (RCTs). Several possible strategies have been 
employed including drug withdrawal upon achievement of treat-
PHQWWDUJHWDQG¿[HGGRVHUHGXFWLRQE\HLWKHUKDOYLQJWKHGRVH
or increasing the time interval between doses (dose-spacing) 
(Figure 1). Dose spacing is generally more favourable and prac-
tical, since half-doses are not always available. This is true for 
SUH¿OOHGV\ULQJHV$KDOIGRVHVWUDWHJ\PD\EHPRUHIHDVLEOHIRU
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,9WKHUDS\RUZKHUHKDOIGRVHVDUHDYDLODEOHHJ(WDQHUFHSW
Enbrel). Another possible strategy is a step-wise dose-reduction 
RIWUHDWPHQWXQWLOWKHGUXJLVGLVFRQWLQXHGRUDGLVHDVHÀDUHRF-
curs (disease activity guided). Fixed-dose reduction and open-
label disease activity guided dose optimisation have largely been 
found to be non-inferior to continuation. Disease activity 
guided tapering is considered to be the best strategy for clinical 
practice. In general, direct withdrawal is considered inferior to 
other methods.
Drug Withdrawal/Stopping
6HYHUDO VWXGLHV KDYH DQDO\VHG WKH H൵HFWV RI E'0$5' ZLWK-
drawal in RA patients, the majority of which involve TNFis. 
They predominantly include patients with early RA and active 
disease who underwent remission induction with a bDMARD in 
order to achieve remission or LDA, followed by treatment with-
drawal.6 In the majority, direct discontinuation of a bDMARD 
OHDGV WR GLVHDVH ÀDUH LQ PDQ\ SDWLHQWV30,33-35 however; a small 
SURSRUWLRQPD\DFKLHYHGUXJIUHHUHPLVVLRQ16
7KH¿UVWE'0$5'ZLWKGUDZDOVWXG\E\4XLQQHWDOVWXGLHG
early RA patients in a double-blind RCT. They demonstrated 
WKDWWUHDWPHQWZLWKPHWKRWUH[DWH07;SOXVLQÀL[LPDE,);
produced rapid improvements in disease activity, physical func-
tion and MRI synovitis scores compared to MTX alone. IFX 
ZDVVWRSSHGDIWHU\HDURISDWLHQWVKDGVXVWDLQHGFOLQLFDO
response and maintenance of quality of life and function at 12 
months.36 Similarly, the RRR study aimed to investigate whether 





mission induction with MTX plus IFX versus MTX plus high-
dose IV methylprednisolone for early RA patients. Those in 
'$6UHPLVVLRQDWZHHNVVWRSSHG,);07;SOXV
IFX was not statistically superior to MTX plus IV steroid in a 
77DSSURDFKRISDWLHQWVWKDWGLVFRQWLQXHG,);UHPDLQHG
in remission until the end of the study.
In the Hit Hard study, a double-blind RCT, very early RA pa-
tients were randomized 1:1 to receive MTX plus placebo ver-
VXV07;SOXVDGDOLPXPDE$'$IRUZHHNV IROORZHGE\
ADA discontinuation, irrespective of disease activity. MTX 
ZDVFRQWLQXHGIRUPRQWKV5HPLVVLRQUDWHVDWZHHNZHUH
VLJQL¿FDQWO\ KLJKHU LQ WKH$'$ JURXS  p  07;
PDLQWHQDQFHWKHUDS\ZDVH൵HFWLYHLQDVLJQL¿FDQWSURSRUWLRQRI
patients for sustaining remission following cessation of ADA. 
Radiographic progression (assessed by the Sharp-van der Heijde 
score) was slightly higher in the MTX group. A similar study 
237,0$LQYHVWLJDWLQJWKHZLWKGUDZDORI$'$IRUSDWLHQWVLQ
VWDEOH /'$ '$6&53 DW ZHHNV IRXQG WKDW SDWLHQWV
ZHUHPRUHOLNHO\WREHLQ/'$vsDQGUHPLVVLRQ
vsDWZHHNVLIWKH\FRQWLQXHG$'$FRPSDUHGWRVWRS-
ping).40 These results are supported by an observational study 





progression was noted for the MTX monotherapy group, during 
the initial RCT.41
,Q WKH (03,5( VWXG\ WKH H൶FDF\ RI (71 SOXV 07; YHUVXV





treatment with ETN did not increase the chance for drug-free 
*ETN=Etanercept; ADA=Adalimumab; S/c=Subcutaneous; DAS28=Disease Activity Score.
Figure 1: An Example of Tapering for Clinical Practice by Fixed-Dose Reduction, by Half Dosing or Dose-Spacing.
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remission.42
For non-TNFis, the CERTAIN study was a small observational 
study involving 23 patients initially treated with certolizumab 
SHJRO&=3DQG07;&=3ZDVGLVFRQWLQXHGLQSDWLHQWVZKR
achieved remission according to the clinical disease activity in-
GH[VFRUH&'$,2QO\UHPDLQHGLQUHPLVVLRQDW
months.43 The DREAM study was a single-arm study in which 
SDWLHQWVZLWKHVWDEOLVKHG5$ZHUHLQLWLDOO\WUHDWHGZLWKWR-
cilizumab (TCZ) monotherapy. TCZ was discontinued at enroll-
PHQWLISDWLHQWVZHUHLQ'$6UHPLVVLRQ/'$$W\HDUIROORZ
XSRQO\ZHUHLQUHPLVVLRQDQG/'$44 In the AVERT 
VWXG\HDUO\5$SDWLHQWVLQLWLDOO\WUHDWHGZLWKVXEFXWD-
neous abatacept (ABA) plus MTX, ABA monotherapy or MTX 
monotherapy for 12 months) discontinued ABA once LDA was 
achieved. At 6 months, more patients were in remission in the 
$%$JURXSVFRPSDUHGWRWKH07;JURXSYHUVXV45
Dose Reduction or Spacing
7KH35,=(VWXG\LVDGRXEOHEOLQG5&7RI(71YHUVXVVWDQGDUG
RIFDUHLQHDUO\5$SDWLHQWV3DWLHQWVUHFHLYHG(71PJZHHN
SOXV 07; WR LQGXFH UHPLVVLRQ '$6(65 RYHU  ZHHNV
2YHUDFKLHYHGUHPLVVLRQ3DWLHQWVZHUHVXEVHTXHQWO\UDQ-
domized to receive either half dose ETN plus MTX, placebo 
SOXV07;RUSODFHERDORQHIRUZHHNV5HPLVVLRQUDWHVZHUH
DQG UHVSHFWLYHO\ GHPRQVWUDWLQJ WKDW WKH OHYHO
of treatment reduction was associated with loss of remission in 
this cohort. Withdrawal of ETN was possible in less than half of 
patients and drug-free remission in a quarter of patients only.46
,Q WKH 35(6(59( VWXG\ HVWDEOLVKHG 5$ Q  SDWLHQWV UH-
FHLYLQJ(71PJZHHNZLWK07;ZHUHUDQGRPL]HGWRHL-
WKHUVWRS WDSHU PJZHHNRUFRQWLQXH WUHDWPHQWEDVHGRQ
WKH DFKLHYHPHQW RI /'$ '$6$IWHU VWRSSLQJ (71 
RISDWLHQWV UHPDLQHG LQ/'$DW\HDU DQGIRU WKH
continuing and tapering groups respectively). Radiographic pro-
gression was reduced in the ETN groups. It was found that stop-
SLQJ(71ZDVDVVRFLDWHGZLWK VLJQL¿FDQWSURJUHVVLRQRI MRLQW
damage.30
DOSERA is a double-blind RCT in which established RA pa-
tients receiving either ETN + MTX were randomized to either 




,Q WKH '5(66 VWXG\ SDWLHQWV ZLWK HVWDEOLVKHG 5$ ZKR
DFKLHYHG /'$ '$6(65!  PRQWKV RQ 07; SOXV HLWKHU
ETN or ADA were randomized 2:1 to gradually taper the bD-
MARD by increasing the time interval versus continuing treat-
PHQW $IWHU  PRQWKV WKH WDSHULQJ VWUDWHJ\ ZDV VKRZQ WR
EH QRQLQIHULRU ZLWK UHVSHFW WR LQFUHDVH LQ ÀDUH '$6(65
FKDQJH! RU '$6(65 LQFUHDVH RI  DQG FXUUHQW '$6-
(6532
The STRASS study investigated the possibility of DAS-driven 
dose-spacing of TNFi injections, according to the T2T strategy. 
3DWLHQWV ZLWK HVWDEOLVKHG 5$ LQ '$6(65 UHPLVVLRQ 
over 6 months were treated with either ADA or ETN (alone or in 
combination with csDMARD). 137 patients were randomized to 
continue full dose TNFi or spacing of the dosing interval. In the 
case of loss of remission, the last dosing regimen was re-intro-
GXFHGRISDWLHQWVZHUHDEOHWRVWRSWKH71)LLQWKHWDSHULQJ
DUP ZKLOVW PDLQWDLQLQJ UHPLVVLRQ  FRXOG WDSHU KRZHYHU
not discontinue treatment. The others resumed full treatment.31
In the BeSt study, four dynamic treatment strategies were com-
pared for the induction of remission for patients with sustained 
UHPLVVLRQ'$6RYHUPRQWKV'0$5'VZHUHWDSHUHG
DQG VWRSSHG ZLWK E'0$5'V VWRSSHG ¿UVW IROORZHG E\ FV'-
MARDs: arm 1, sequential monotherapy (n=126); arm 2, step 
up combination therapy (n=121); arm 3, initial combination 
therapy with prednisolone (n=133) and arm 4, initial combina-
WLRQWKHUDS\ZLWK07;DQG,);$SSUR[LPDWHO\KDOIRI
patients reached remission. Drug-free remission was achieved in 
LQDUPLQDUPLQDUPDQGDUP
relapsed, the majority of which regained remission when intro-
ducing the last therapeutic regimen.
The RETRO study is an RCT comparing treatment strategies in 
HVWDEOLVKHG5$SDWLHQWVLQ'$6(65UHPLVVLRQRYHUPRQWKV




of patients maintained their remission state.
,QWKH$*5((VWXG\SDWLHQWVZLWKHDUO\5$LQ'$6UH-
mission were randomized 1:1 to standard versus half dose IV 
ABA. They initially received treatment in combination with 
MTX for 1 year. Remission rates were slightly higher in the full 
GRVHDUPYHUVXV50
Although, general conclusions can be drawn from these studies, 
it is important to recognize that several limitations exist, con-
tributing to variability in outcomes. Considerable heterogeneity 
exists in terms of the methods used, criteria used for patient se-
OHFWLRQDQGGH¿QLWLRQVRIÀDUHVXVWDLQHGUHPLVVLRQ,QDGGLWLRQ
PRVW VWXGLHV KDYH XVHG WKH $&5 FODVVL¿FDWLRQ FULWHULD51 
IRU5$ZKLFKFRQVHTXHQWO\PD\KDYHOHGWRPLVFODVVL¿FDWLRQRI
some patients.16
WHO AND WHEN TO TAPER?
'HVSLWH WKH UHFRJQLVHGEHQH¿WVRIE'0$5'WDSHULQJDQG WKH
evidence to support its implementation in a proportion of pa-
tients, there is a paucity of evidence to guide clinicians on such 
a change in treatment focus.52
Logically, tapering should only be applied in patients who have 
achieved their target treatment goal. As demonstrated by the 
existing studies, the best target population for tapering are pa-
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WLHQWVLQDVXVWDLQHGVWDEOHVWDWHLGHDOO\UHPLVVLRQGH¿QHGFOLQL-
cally (based on clinical experience and data from clinical tri-
als). The majority of clinical trials exploring bDMARD 
discontinuation or tapering have done so based on patients 
DFKLHYLQJVXVWDLQHG'$6/'$RUUHPLVVLRQRYHUDSHULRGRI
6 months.&XUUHQWHYLGHQFH VXJJHVWV WKDWSDWLHQWV LQ'$6
remission are heterogeneous in terms of clinical, immunological 
and imaging characteristics, with a proportion of patients still 
GLVSOD\LQJ FOLQLFDO VLJQV DQG V\PSWRPV RI LQÀDPPDWLRQ DQG
sub-clinical synovitis on US.53 Furthermore, radiographic pro-
gression has been demonstrated in some patients.54 It has there-
IRUHEHHQVXJJHVWHGWKDW'$6PD\DFWXDOO\UHSUHVHQWPLQLPDO
disease activity rather than a true state of remission and is not the 
best selection criteria for tapering.6 Most studies of bDMARD 
WDSHULQJZHUHFRQGXFWHGSULRUWRWKHGHYHORSPHQWRIWKH$&5
Boolean remission criteria however, the RETRO study did not 
¿QG DQ\ DGGLWLRQDO EHQH¿W LQ XVLQJ WKLV VWULFWHU GH¿QLWLRQ WR




dance of literature proposing both imaging and immunological 
ELRPDUNHUV HLWKHU DORQH RU LQ FRPELQDWLRQ WR FKDUDFWHUL]H D
true remission state however, none have entered routine clini-
FDOSUDFWLFH7KHQRWLRQRIµGHHS¶UHPLVVLRQGH¿QHGFOLQLFDOO\
DVD'$6KDVEHHQVXJJHVWHGDQGWKRXJKWWRUHÀHFWWKH
DEVHQFHRIELRORJLFDOLQÀDPPDWLRQ55 (not routinely used in prac-
WLFH0RUHVSHFL¿FDOO\WKHQRWLRQRIPROHFXODULPPXQRORJLFDO
UHPLVVLRQ 5)RU$&3$QHJDWLYLW\RUHYLGHQFHRI VHURFRQYHU-









the transferability of such measures to clinical practice.
PREDICTORS OF SUCCESSFUL TAPERING/DISCONTINUATION
,QRUGHUWRGH¿QHWKHUHPLVVLRQVWDWHPRUHREMHFWLYHO\LWLVFULWL-
cal to identify independent predictors of disease relapse to help 
inform tapering decisions. Response prediction is well estab-
lished in other medical specialties e.g., Oncology, where Her2 




Clinical and Demographic Predictors
$QXPEHURIFOLQLFDOSUHGLFWRUVKDYHEHHQLGHQWL¿HGZKLFKPD\
DLG WKH GHFLVLRQ PDNLQJ SURFHVV /RQJHU GLVHDVH GXUDWLRQ KDV
EHHQVKRZQWREHDFUXFLDOULVNIDFWRUIRUSURJUHVVLYHGLVHDVH52 
6SHFL¿FDOO\ WKH+2125VWXG\GHPRQVWUDWHG WKDW VKRUWHUGLV-
ease duration was a baseline predictor for ADA free remission.41 
7KLV LV VXSSRUWHGE\ WKHSUHOLPLQDU\DQDO\VHV IURP WKH32(7
study.
7KHVH ¿QGLQJV VXSSRUW WKH µZLQGRZ RI RSSRUWXQLW\¶ K\SRWK-
esis that aggressive therapy in the early stage of disease can 
OHDGWRLPSURYHGRXWFRPHVDQGVXVWDLQHGEHQH¿WWKHOLNHO\UHD-
son being that there is potential reversibility of autoimmunity in 
the early stages of disease. It is therefore regarded that remission 
induction during this phase increases the chance of successful 
tapering of bDMARDs to maintenance therapy. This reversibil-




less of a chance of drug free remission.16 This concept is sup-
SRUWHGE\ WKHREVHUYDWLRQ WKDW WKHUDSHXWLFUHVSRQVH LQ WKH¿UVW
3 months of treatment can predict the potential for achieving 
remission later.61
Baseline disease activity and the quality of clinical remission 
has also been shown to be predictive of successful discontinua-
tion of TNFis.556SHFL¿FDOO\WKHFXWR൵SRLQWVLQWKH555DQG
+2125VWXGLHVZDVDEDVHOLQH'$6VFRUHRIDQG
respectively, supporting the notion that deep remission i.e. no 
UHVLGXDO LQÀDPPDWLRQ LVQHFHVVDU\IRUVXFFHVVIXOGLVFRQWLQXD-
tion.37,41,QWKH237,0$VWXG\JRRGEDVHOLQHIXQFWLRQDOVWDWXV
at discontinuation of ADA, as assessed by standardized patient 
reported outcome measures, was found to predict sustained low 
disease activity.40 El Miedany et al also found that worsening 
IXQFWLRQDO GLVDELOLW\ LV DVVRFLDWHG ZLWK GLVHDVH ÀDUH55 Similar 
¿QGLQJVZHUHIRXQGLQWKH$9(57VWXG\45 In addition, longer re-
PLVVLRQGXUDWLRQORQJHUGXUDWLRQRI71)LWKHUDS\QRQVPRNLQJ
status, negative shared epitope, younger age and female gender 
have been shown to be predictive of successful discontinuation 
of TNFis.37,47,62 Barral et al recently conducted a study to develop 
a predictive score for successful TNFi tapering, based on clini-
FDODVVHVVPHQWV7KH\IRXQGWKDWEDVHOLQH+$4DQG&53ZHUH
independent predictors. They have developed a composite score 
ZLWKDQ$8&RIDQGVSHFL¿FLW\KRZHYHUWKLVQHHGV
validation.63
7KH W\SH RI E'0$5' XVHG PD\ DOVR LQÀXHQFH WKH DELOLW\ WR
VXFFHVVIXOO\WDSHU1RJUHDWGL൵HUHQFHVKDYHEHHQLGHQWL¿HGEH-
tween TNFis however; the DREAM study demonstrated high 
relapse rates for patients treated with tocilizumab. It has been 
suggested that standardised treatment regimens may in fact over 
WUHDW DSURSRUWLRQRISDWLHQWVE\XVLQJ WKHPD[LPXPH൵HFWLYH
dose at group level.
Imaging Predictors
3K\VLFDOH[DPLQDWLRQLVNQRZQWRKDYHDORZVHQVLWLYLW\IRUWKH
detection of mild synovitis, such as that found in clinical remis-
sion, however,64PXVFXORVNHOHWDO86KDVSURYHQWREHDQH[FHO-
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OHQWWRROWRLGHQWLI\VXEFOLQLFDOLQÀDPPDWLRQ53 
7KH UROH RI LPDJLQJ LQ 5KHXPDWRORJ\ KDV JDLQHG VLJQL¿FDQW




when assessed with US. In accordance with other studies, these 
¿QGLQJ DSSHDU WR EH WKH UHDVRQ ZK\ UDGLRJUDSKLF SURJUHVVLRQ
occurs in many cases.66
Since US has demonstrated to be a reliable method of predicting 
relapse in patients in clinical remission,67 there is interest in us-
ing this tool to identify patients who may taper biologic therapy. 
$SURVSHFWLYHVWXG\IURP,WDO\GHPRQVWUDWHGWKDW3'V\QRYLWLV








that grey scale synovial hypertrophy has a predictive value for 





logical characteristics of synovial tissue in long standing RA pa-






assessed by grey scale changes were independent predictors of 
UHODSVH,QDGGLWLRQ$&3$SRVLWLYLW\DQGZRUVHQLQJIXQFWLRQDO
disability were helpful when combined with US.55 In contrast to 
WKHSUHYLRXVVWXGLHVSUHOLPLQDU\DQDO\VHVIURPWKH32(7VWXG\
KDYHGHPRQVWUDWHGWKDW86ZDVRQO\DPRGHVWSUHGLFWRURIÀDUH
in the individual patient when combined with clinical measures; 
however it was a better predictor at the group level.72 Ultraso-
nography is not the only imaging technique capable of assess-
LQJVXEFOLQLFDODFWLYLW\VHYHUDOVWXGLHVKDYHFRQ¿UPHGWKDWERQH
marrow oedema on magnetic resonance imaging (MRI) is pre-
dictive of structural damage in the joint.73,74 Brown et al were the 
¿UVW WRGHPRQVWUDWH WKDW VXEFOLQLFDO LQÀDPPDWLRQRQ05,DQG
ultrasound could predict poor radiographic outcomes.54 Krabben 
et al75KDGVLPLODU¿QGLQJVDQG2VWHUJDDUG et al found an associa-
tion between synovial membrane volume (determined by MRI) 
and the rate of progression with bone destruction.76 In contrast, 
D SURVSHFWLYH VWXG\ E\ )ROW] HW DO GLG QRW VXSSRUW WKH ¿QGLQJ
WKDW05,FDQSUHGLFWGLVHDVHSURJUHVVLRQRQO\3'FRXOG1HY-
HUWKHOHVV WKH\EHOLHYHWKDW WKHXVHRIORZ¿HOG05,DQGVKRUW
delay between radiographic assessments could have biased the 
results.77 In spite of promising outcomes, MRI has not entered 
routine practice due to its elevated cost.
Concerning other imaging techniques, computed tomography 
(CT) has generally been discarded as a tool to monitor disease 
activity as it requires high doses of radiation. On the other hand, 
X-rays generally do not seem to be useful for predicting pro-
JUHVVLRQDVWKH\JLYHLQIRUPDWLRQRISDVWLQÀDPPDWLRQ%\WKH
time erosions are seen on X-ray, structural damage has already 
occurred.76 Interestingly, a recent systematic reviewby Twee-
huysen et al found that radiographic erosions, as assessed by 
WKH6KDUS9DQGHU+HLMGHVFRUHZDVZHDNO\SUHGLFWLYHRISUR-
gression probably by identifying more severe or longer duration 
disease.
,Q OLJKWRI WKHVH¿QGLQJV WKHXVHRI VHQVLWLYH LPDJLQJDVVHVV-
ments particularly US, either alone or in combination with clini-
cal assessments could assess remission more objectively and 
represent a starting point to identify the best candidate for bD-
MARD tapering. This strategy is yet to enter routine practice, 
perhaps due to cost and resource allocation.
Immunological Predictors 
In addition to imaging assessments it has been attempted to eval-
uate immune activity using serological tests for a more objective 




maintaining remission status in the RETRO study. Other stud-
ies including BeST, Hit-Hard and preliminary results from the 
32(772VWXG\VXSSRUWWKHVH¿QGLQJV,QFRQWUDVWDVPDOOVWXG\
E\6DOHHPHWDOGLGQRW¿QGWKLVDVVRFLDWLRQ Van der Woude, 
et al conducted a DAS-driven versus a non-DAS-driven dose re-
duction trial with a cohort of more than 500 patients. As well as 
LGHQWLI\LQJWKHDEVHQFHRI$&3$5)DQGVKDUHGHSLWRSHDOOHOHV
were found to be independent predictors for sustained remission. 
7KH\KLJKOLJKWHGWKDW$&3$SRVLWLYHSDWLHQWVLQWKH'$6GULYHQ
cohort had a slightly higher probability of achieving drug-free 
remission, suggesting that DAS-driven therapy could compen-
VDWHWKHGLVDGYDQWDJHRIEHLQJ$&3$SRVLWLYH 
7DQDNDHWDODOVRIRXQGWKDWWKHSUHVHQFHRI5)ZDVDVVRFLDWHG
with lower chance of successful withdrawal of TNFis. This 
¿QGLQJLVDOVRVXSSRUWHGE\WKH5(752'5($0DQG675$66
studies. In a study by El Miedany et al 172 patients re-
ceived either a bDMARD (TNFi, TCZ or ABA) or csDMARD 




There has been recent interest in measuring T-cell subsets to 
assess immune activity in RA patients. In a study compar-
ing the characteristics of 47 patients undergoing TNFi tapering, 
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sustained remission was associated with low levels of immuno-
logical abnormalities. More precisely, patients who sustained 
UHPLVVLRQ IRU  PRQWKV SUHVHQWHG D KLJKHU IUHTXHQF\  RI
QDwYH 7FHOOV DQG ORZHU IUHTXHQF\ RI ,QÀDPPDWLRQUHODWHG
Cells (IRC). In addition, the frequency of T-regulatory (Treg) 
cells was higher in the sustained remission group, particularly 
for the CD62L+ subgroup. Interestingly, these proportions were 
GL൵HUHQW IRU WKH SDWLHQWV UHFHLYLQJ HDUO\ DJJUHVVLYH WUHDWPHQW
compared to those whose treatment was delayed, for whom Treg 
frequency was higher.
6WXGLHVRI LPDJLQJDQG LPPXQRORJLFDOELRPDUNHUVQHHG WREH
UHSOLFDWHGLQODUJHUFRKRUWVZLWKDSUHGH¿QHGWDSHULQJSURWRFRO
before they can be considered predictors. Several studies are 




LQÀDPPDWLRQ PDUNHUV PLJKW VXJJHVW EHWWHU FRQWURO RI LQÀDP-
PDWRU\GLVHDVHVHUXPPDUNHUVRILQÀDPPDWLRQKDYHDOVREHHQ
studied as predictors of drug-free remission in RA. Although 
PHDVXUHVRI&53DQG(65DUHZLGHO\XVHGWRDVVHVVLQÀDPPD-
WLRQLQ5$WKHVHDUHQRQVSHFL¿FDQGGRQRWDVVHVV WKHORFDO-
LVHG LQÀDPPDWRU\ DFWLYLW\UHODWHG SURFHVVHV VXFK DV VWUXFWXUDO
degradation at the joint level.6 $FRPSRVLWH PXOWLELRPDUNHU
disease activity (MBDA) score has been established to better 
GH¿QHUHPLVVLRQ,WLQYROYHVDWRWDORILQÀDPPDWLRQSDUDP-
HWHUV LQFOXGLQJ PDUNHUV OLQNHG WR WKH DFXWH SKDVH UHVSRQVH
>&53,QWHUOHXNLQ,/DQGVHUXPDP\ORLG6$$@ORFDOWLV-
VXH LQÀDPPDWLRQ PDUNHUV >7XPRXU QHFURVLV IDFWRU UHFHSWRU
(TNFRI), epidermal growth factor (EGF),vascular endothelial 
growth factor-A (VEGF-A) and vascular cell adhesion mol-
HFXOH9&$0H[SUHVVHGE\DFWLYDWHGV\QRYLDO¿EUREODVWV@
ORFDO WLVVXH UHPRGHOOLQJ PDUNHUV>0DWUL[ PHWDOORSURWHLQDVH
DQG003	DQGKXPDQFDUWLODJHJO\FRSURWHLQ<./
DQGDGLSRNLQHVUHVLVWLQDQGOHSWLQ It was initially devel-
RSHGDQGYDOLGDWHGWRFRUUHODWHZLWKWKH'$6&53VFRUH
Several studies have shown an association with high MBDA and 
radiographic progression, two have demonstrated the score 
to be a better predictor for radiological progression than the 
'$6&53VFRUH
Two major bDMARD tapering studies have utilised the MBDA 
score. The RETRO study showed that the MBDA score didnt 
GL൵HUDFFRUGLQJWR$&3$SRVLWLYLW\1HYHUWKHOHVVLIFRPELQHG
ZLWK$&3$WHVWLQJLWFRXOGSUHGLFWWKHUHODSVHRIPRUHWKDQ
of the patients if both were positive. Only double positive or 
GRXEOHQHJDWLYH UHVXOWV IRU$&3$DQG0%'$ZHUHSUHGLFWLYH
RI UHVSHFWLYH UHODSVH RU VXVWDLQHG UHPLVVLRQ 6WULNLQJO\ ZKLOH
MBDA scores were higher at baseline and during a relapse in 
WKHWDSHULQJJURXSVLQWKHQRQWDSHULQJJURXSLWGLGQRWGL൵HU
between relapsing and sustained remission patients. The RET-
52VWXG\DOVRVKRZHGWKDW$&3$DQG0%'$FRQWULEXWHGLQGH-
SHQGHQWO\WRWKHULVNRIUHODSVHGXULQJGRVHUHGXFWLRQDQGLQD
recent study by Hagen et al the combination of MDBA score 
DQG$&3$ VWDWXV DOORZHG IRU VXFFHVVIXO '0$5' WDSHULQJ LQ
patients enrolled on the RETRO study, suggesting that both au-
WRLPPXQLW\DQGLQÀDPPDWLRQDUHLQYROYHGLQWKHULVNRIUHODSVH
of in RA patients undergoing bDMARD tapering. Interestingly, 
QRGL൵HUHQFHZDVUHYHDOHGZKHQ0%'$ZDVUHSODFHGE\&53
ESR, CDAI or SDAI. On the other hand, the DRESS study 
contradicts these results. They showed that neither baseline 
0%'$QRU$&3$ZHUHSUHGLFWLYHRIÀDUHLQWKHWDSHULQJJURXS
but they were in the usual care group. The design of this study 
ZDVGL൵HUHQWIURPWKHRWKHUVGLVFXVVHGZKHUHSDWLHQWVZHUHLQ
LDA rather than remission, with long standing RA.
$GGLWLRQDOHYLGHQFHWRVXSSRUWWKHXVHRIVHURORJLFDOELRPDUN-
ers to predict success of tapering is demonstrated in a study of 





mation by laboratory testing may be a useful tool to determine 
ULVNRIÀDUHKLJKULVNFDQGLGDWHVLQZKRPWDSHULQJVKRXOGQRWEH
LQLWLDWHG)XUWKHUZRUNLVQHHGHGWRYDOLGDWHWKHVHELRPDUNHUV$
prospective trial currently in progress (VECTRA-DA) will anal-
yse the MBDA score to evaluate rigorously its potential use in 
patients management.
Serum Drug/anti-Drug Antibody Levels
$ VWXG\ LQ  PRQLWRUHG LQÀL[LPDE WURXJK OHYHO DQWLERGLHV
GXULQJWDSHULQJDFFRUGLQJWR'$6&53PHDVXUHV,WUHYHDOHG
considerable variations between patients. Trough levels tended 
to decrease with the reduction of the medication dose and a low-
HUOHYHORILQÀL[LPDEZDVIRXQGLQWKHSDWLHQWVZLWKDQWLLQÀL[-
LPDE DQWLERGLHV (YHQ WKRXJK WKH '$6 UHPDLQHG UHODWLYHO\
constant for most of the patients before and after dose reduc-
WLRQLQÀL[LPDEOHYHOVZHUHKLJKO\YDULDEOHIURPRQHWRDQRWKHU
0RUHRYHU WKHRQHSDWLHQW WKDWÀDUHGDW WKH¿UVWYLVLWKDGKLJK
LQÀL[LPDEOHYHOVDQGQRDQWLGUXJDQWLERGLHV$QDO\VLVRIWURXJK
levels were retrospective. And a prospective study should be in-
teresting for the prediction of tapering success.
In 2016, another study involving 64 patients receiving ADA as 
WKHLU¿UVWELRORJLFXQGHUZHQWDUHGXFWLRQLQWUHDWPHQWGRVH
DQG ZHUH IROORZHGXS IRU  ZHHNV 0HGLFDWLRQ WURXJK OHYHO
$'$DQWLERGLHVDQGFKDQJHRI'$6&53ZHUHPHDVXUHG,W
VKRZHGWKDW$'$OHYHOVFRUUHODWHGZLWKWKH'$6&53EHIRUH
and after the medication reduction. They also witnessed that pa-
WLHQWVZLWK$'$DQWLERGLHVKDGVLJQL¿FDQWO\ORZHUWURXJKOHY-
els, and also had worse methotrexate compliance. All of them 
relapsed during the study. A more recent study evaluated base-
line ADA, ETN and IFX drug levels and their antibodies during 
dose reduction. It revealed that they were not predictive of suc-
cess for reduction or discontinuation of treatment. One possible 
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Other Predictors
In relation toTNFi treatments, it has been suggested that TNF 
gene polymorphisms and variability of TNFi response may pre-
dict better drug responsiveness and better chance for tapering.57
As previously mentioned, Schett et al suggest that the attainment 
of deep remission requires the achievement of remission at mul-
WLSOHOHYHOV7KLVLQFOXGHVUHPLVVLRQGH¿QHGE\FOLQLFDODVVHVV-
PHQWV LPDJLQJ DVVHVVPHQWV 8605, VHURORJLFDO DEVHQFH
RI LQÀDPPDWLRQ QRUPDO LQÀDPPDWRU\ PDUNHUV DQG QHJDWLYH
DXWRDQWLERGLHVIRU5)DQG$&3$7KLVFRXOGSRWHQWLDOO\IRUP
WKHEDVLVRIR൵HULQJWDSHULQJLQWKHIXWXUHKRZHYHUWKHUHDUHFXU-
rently no studies assessing the predictive value of deepremission 
for successful tapering of bDMARDs.
CONCLUSION
Evidence supports that tapering or discontinuation of bDMARDs 
is feasible in a sub-set of patients who have achieved clinical re-
PLVVLRQKRZHYHUWKHLGHDOSDWLHQWSUR¿OHLV\HWWREHGH¿QHG
%LRPDUNHUEDVHGSUHGLFWLRQLVQRW\HWUHDG\IRUFOLQLFDOSUDFWLFH
therefore we are obliged to continue to use clinical remission 
criteria, in-line with national guidance. It is therefore critical to 
LGHQWLI\PRUHUREXVWELRPDUNHUVDQGYDOLGDWHH[LVWLQJELRPDUN-
ers, towards providing targeted treatment. This would be better 
than current disease activity guided tapering methods, which are 
based on trial and error. Achieving a state of deep remission, fol-
lowed by gradual tapering of bDMARD appears to be the most 




concerns and costs. It is recommended that strict disease activ-
LW\PRQLWRULQJDQGSDWLHQWHGXFDWLRQRQUHFRJQLVLQJÀDUHVKRXOG
also be employed. Future tapering studies may provide new 
insights into disease pathogenesis and disease course. Further 
ZRUNLVQHHGHGWRH[SORUHWKHUROHRIJHQHWLFDQGHQYLURQPHQ-
tal factors that allow re-establishment of immune tolerance. We 
VKRXOGDOVRFRQVLGHU WKHSUHVHQFHH[WUDDUWLFXODU LQÀDPPDWLRQ
in patients who are in clinical remission, since patients may ben-
H¿W IURPRQJRLQJ WKHUDS\ WRSUHYHQW FDUGLRYDVFXODUPRUWDOLW\
7KHUHIRUH ELRPDUNHUV RI V\VWHPLF LQÀDPPDWLRQ PD\ SURYLGH
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